retatrutide phase 2 weight loss Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide: The New Triple-Agonist Weight
Description
SGLT2i also decrease insulin resistance, blood pressure and body mass, while not causing hypoglycemia (124)
Most community protocols use a 24-week staggered titration to reach maintenance, then run open-ended at maintenance with periodic re-evaluation
Knowing how it works, lets discuss the dosage and method of administering semaglutide
doi: 10.1016/j.curtheres.2018.09.001
Histamine-2 receptor antagonists (H2RAs) such as famotidine, cimetidine, or nizatidine offer a less potent but reasonable alternative
